Denali grabs another megaround while inking a flurry of neurodegeneration R&D pacts
South San Francisco-based upstart Denali Therapeutics has been busy. A little more than a year after making a splash with its $217 million startup round designed to fund a new breed of neurodegeneration drug developer, the biotech is back with another megaround financing and a string of deals topped by a move into the clinic for its lead drug.
Denali is going big, early on. The second chapter in Denali’s story starts with a $130 million Series B, bringing its total close to $350 million. And it’s lining up a Phase I study for a small molecule RIP1 inhibitor targeting glial dysfunction, where Denali hopes to start establishing a track record for success against ALS and Alzheimer’s.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.